

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Harald Kropshofer, Till Alexander Roehn, Anne Vogt

Case Docket 21412

For: **NOVEL MHC II ASSOCIATED PEPTIDES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
October 1, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents C1-C48 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Agent for Applicant(s)
Lyman H. Smith
(Reg. No. 44342)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-3916
Telefax: (973) 235-2363

134736

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				
		Complete if Known		
		Application Number		
		Filing Date		
		First Name Inventor	Harald Kropshofer et al.	
		Group Art Unit		
		Examiner Name		
Sheet	3	Of	3	
			Attorney Docket Number	21412

NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature** _____ **DATE
CONSIDERED** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

Unique citation
134470

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>				Complete if Known	
				Application Number	
				Filing Date	
				First Name Inventor	Harald Kropshofer et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	3	Attorney Docket Number	21412

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Kropshofer et al., Immunol. Today, 18, pp. 77-82 (1997)	
	C2	Dallal et al., Curr. Opinion Immunol., 12, pp. 583-588 (2000)	
	C3	Timmerman et al., Annu. Rev. Med., 50, pp. 507-529 (1999)	
	C4	Nestle et al., Nature Medicine, 7, pp. 761-765, (2001)	
	C5	Ridge et al., Nature, 393, pp. 474-478 (1998)	
	C6	Wang, Rong-Fu, Trends in Immunol., 22, pp. 269-276 (2001)	
	C7	Thurner et al., J. Exp. Med., 190, pp. 1669-1678 (1999)	
	C8	Nestle et al., Nature Medicine, 4, pp. 328-332 (1998)	
	C9	Boon et al., Ann. Rev. Immunol., 12, pp. 337-365 (1994)	
	C10	Germain, Ronald N., Cell, 76, pp. 287-299 (1994)	
	C11	Banchereau et al., Nature, 392, pp. 245-254 (1998)	
	C12	Chicz et al., J. Exp. Med., 178, pp. 27-47 (1993)	
	C13	Wang et al., J. Exp. Med., 189, pp. 1659-1667 (1999)	
	C14	Zarour et al., Cancer Research , 62, pp. 213-218 (2002)	
	C15	Eichmüller et al., Exp. Dermatol., 11, pp. 292-301 (2002)	
	C16	Topalian et al., Proc. Natl. Acad. Sci., 91, pp. 9461-9465 (1994)	
	C17	Manici et al., J. Exp. Med., 189, pp. 871-876 (1999)	
	C18	Zarour et al., PNAS, 97, pp. 400-405 (2000)	
	C19	Li et al., Cancer Immunol Immunother, 47, pp. 32-38 (1998)	
	C20	Pieper et al., J. Exp. Med., 189, pp. 757-765 (1999)	
	C21	Wang et al., J. Exp. Med., 183, pp. 1131-1140 (1996)	
	C22	Stern et al., Nature, 368, pp. 215-221 (1994)	
	C23	Gütgemann et al., Arch Dermaol Research, 293, pp. 283-290 (2001)	
	C24	Lang et al., Prostate, 52, pp. 253-263 (2002)	
	C25	Stassar et al., Br. J. Cancer, 85, pp. 1372-1382 (2001)	
	C26	Kerekattle et al., Int. J. Cancer, 64, pp. 27-31 (1995)	
	C27	Eberle et al., Int. J. Cancer, 71, pp. 396-401 (1997)	
	C28	Vaarala et al., Lab. Invest., 80, pp. 1259-1268 (2000)	
	C29	Richardson, D. R., Eur. J. Biochem., 267, pp. 1290-1298 (2000)	
	C30	Chi et al., Am. J. Pathol., 150, pp. 2143-2152 (1997)	

Examiner Signature		DATE CONSIDERED	
--------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.